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Introduction
hemoptysis
•  A common, non-specific symptom of various 
lung pathologies such as infection, 
bronchiectasis, pulmonary embolism, 
connective tissue disorders, and neoplasms
•  Uncommonly reported in cases related to 
E-cigarette or Vaping Associated Lung  
Injury (EVALI)
Case Report
A 23-year-old male with a history of polysubstance 
abuse and daily vaping presented with sudden 
onset shortness of breath and hemoptysis 
which woke him up from sleep. He was found 
to be in hypoxic respiratory failure and placed 
on high flow oxygen via nasal cannula. Labs 
revealed a leukocytosis, elevated creatinine,  
mild troponin elevation, and a lactic acidosis. 
Computed tomography (CT) chest angiogram 
revealed bilateral ground glass opacities without 
evidence of pulmonary embolism. Urine toxicology 
screen was positive for cannabinoids and opioids. 
His symptoms resolved and lab abnormalities 
corrected with fluid resuscitation and without 
antibiotics. He was diagnosed with EVALI with 
bilateral pneumonitis and was discharged within 
48 hours after admission. At discharge, he was 
counseled to cease any form of vaping. 
Figure 2. Worsening ground-glass opacities on repeat CT-scan in the 
setting of continued e-cig usage.
Figure 1. Bilateral Ground-glass opacities noted on initial presentation.
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He returned to the emergency department 
multiple times in a two-month span and was 
readmitted twice due to recurrent hemoptysis in 
the setting of continued vaping. He was noted 
to have elevated creatine kinase and lactate levels. 
Repeat CT chest with contrast five weeks after 
initial imaging showed worsening bilateral diffuse 
ground-glass opacities and interstitial infiltrates. 
Autoimmune and neurologic workup was 
negative. Bronchoscopy with bronchial alveolar 
lavage and cultures was unremarkable. After 
multidisciplinary discussions, he was initiated on 
high dose steroids. At his four-week follow up, 
his respiratory symptoms had resolved with 
cessation of vaping. A repeat CT chest revealed 
complete resolution. He finished a gradual 
steroid taper with no recurrence of his hemoptysis. 
Discussion
evali
•  Has become a national emergency with a 
growing number of cases in patients who use 
vaping products in the last year
•  Predominantly seen in patients under the age 
of thirty-five
•  Strongly associated with the use of tetrahydro-
cannabinol containing products and is less 
commonly seen with nicotine containing 
products, as demonstrated in our patient
•  Common symptoms include dyspnea, chest 
congestion and cough, with hemoptysis only 
reported in 11% of the cases
•  Symptoms such as hemoptysis can improve 
when a patient ceases vaping. 
Figure 3. Complete resolution of ground-glass opacities after halting 
e-cig usage. 
Conclusion
•  Importance of having a high index of 
suspicion for EVALI in patients who present 
with respiratory symptoms or hemoptysis in 
the setting of current or previous e-cigarette 
or vaping use
•  Prevention and cessation of vaping is 
paramount to reduce overall incidence  
of EVALI.
